Skip to Main Content

Key Features

Essentials of Diagnosis

  • Hemophilia A: congenital deficiency of coagulation factor VIII

  • Hemophilia B: congenital deficiency of coagulation factor IX

  • Recurrent hemarthroses and arthropathy

  • Risk of development of inhibitory antibodies to factor VII or factor IX

  • In many older patients, infection with HIV or hepatitis C virus occurred from receipt of contaminated blood products

General Considerations

  • Inheritance is X-linked recessive, leading to affected males and carrier females

  • There is no race predilection

  • Inhibitors to factor VIII will develop in ~20–25% of patients with severe hemophilia A

  • Inhibitors to factor IX will develop in < 5% of patients with severe hemophilia B

  • Hemophilia is classified according to the level of factor activity in the plasma

    • Mild hemophilia is characterized by > 5% factor activity

    • Moderate hemophilia is characterized by 1–5% factor activity

    • Severe hemophilia is characterized by < 1% factor activity

Demographics

  • The frequency of hemophilia A is ~1 per 5000 live male births

  • Hemophilia B occurs in ~1 in 25,000 live male births

Clinical Findings

Symptoms and Signs

  • Severe hemophilia presents in infant males or in early childhood with spontaneous bleeding into joints, soft tissues, or other locations

  • Spontaneous bleeding is rare in patients with mild hemophilia, but significant bleeding may occur during a major hemostatic challenge (eg, surgery, trauma)

  • Intermediate clinical symptoms are seen in patients with moderate hemophilia

  • Female carriers are can have a wide range of factor VIII activity, with some manifesting a bleeding disorder

  • Joint disease

    • Significant hemophilic arthropathy

      • Usually does not develop in patients who have received long-term prophylaxis with factor concentrate in early childhood

      • Is common in adults who have experienced recurrent hemarthroses

    • Patients tend to have one or two 'target' joints into which they bleed most often

  • Development of inhibitor to factor VIII or factor IX is characterized by bleeding episodes that are resistant to treatment with clotting factor VIII or IX concentrate, and by new or atypical bleeding

Differential Diagnosis

  • Hemophilia B

  • von Willebrand disease

  • Disseminated intravascular coagulation

  • Heparin administration

  • Acquired factor deficiency or inhibitors (eg, paraproteins with anti-VIII or anti-IX activity)

Diagnosis

Laboratory Tests

  • An isolated reproducibly low factor VIII or factor IX activity level, in the absence of other conditions

  • If the aPTT is prolonged, it typically corrects upon mixing with normal plasma

  • Depending on the level of residual factor VIII or factor IX activity and the sensitivity of the thromboplastin used in the aPTT coagulation reaction, the aPTT may or may not be prolonged (although it typically is markedly prolonged in severe hemophilia)

  • In the presence of an inhibitor to factor VIII or factor IX, there is accelerated clearance of infused factor and suboptimal or absent rise in measured activity of infused factor, and the ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.